Creative Medical Technology (CELZ) vs Scinai Immunotherapeutics (SCNI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Creative Medical Technology is the larger company by market cap ($6.4 million vs $1.6 million), about 4.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CELZ | SCNI |
|---|---|---|
| Share price | $0.842 | $1.18 |
| Market cap | $6.39M | $1.60M |
| 1-day change | -2.12% | -2.48% |
| P/E ratio (TTM) | — | 0.04 |
| EPS (TTM) | $-2.07 | $28.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.25 | $15.65 |
| 52-week low | $0.62 | $1.06 |
| Distance from 52-week high | -86.53% | -92.46% |
| Analyst consensus | none | — |
| Avg. price target upside | +2275.30% | — |
| Average volume | 6.77M | 1.10M |
| Shares outstanding | 7.59M | 1.35M |
| Employees | 4 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Creative Medical Technology is about 4.0 times larger than Scinai Immunotherapeutics by market value ($6.39M vs $1.60M).
About Creative Medical Technology
CELZ stock →Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 4 employees
About Scinai Immunotherapeutics
SCNI stock →Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees
CELZ vs SCNI FAQ
Which is bigger, Creative Medical Technology or Scinai Immunotherapeutics?
Creative Medical Technology (CELZ) is larger, with a market capitalization of $6.39M compared with $1.60M for Scinai Immunotherapeutics (SCNI).
Are Creative Medical Technology and Scinai Immunotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.